Zubsolv

Pain, Itching, Septic Shock + 7 more
Treatment
8 FDA approvals
14 Active Studies for Zubsolv

What is Zubsolv

NaloxoneThe Generic name of this drug
Treatment SummaryBuprenorphine is a medication used to treat severe pain and opioid addiction. It is sold under the name Suboxone and is formulated with naloxone, a drug that blocks the effects of opioids if injected. Buprenorphine is taken sublingually (under the tongue) and works by binding to opioid receptors in the brain to reduce pain or withdrawal symptoms. It has a long-lasting effect and can be taken once a day, which reduces the risk of overdose or side effects. Buprenorphine is also used in Opioid Agonist Treatment (OAT) or Opioid Subst
Narcanis the brand name
image of different drug pills on a surface
Zubsolv Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Narcan
Naloxone
1971
241

Approved as Treatment by the FDA

Naloxone, otherwise called Narcan, is approved by the FDA for 8 uses including Pain and Opioid Dependence .
Pain
Used to treat moderate Pain in combination with Pentazocine
Opioid Dependence
Used to treat Opioid Dependence in combination with Buprenorphine
Septic Shock
Pain
Used to treat Severe Pain in combination with Pentazocine
Opioid-Related Disorders
Used to treat Opioid Dependence in combination with Buprenorphine
Septic Shock
Opioids
Respiratory Insufficiency

Effectiveness

How Zubsolv Affects PatientsBuprenorphine is an opioid painkiller that works by binding to mu-receptors in the brain, spine, and other parts of the body. It can produce feelings of relaxation, euphoria, and drowsiness, as well as reduce coughs and shrink pupil size. Taking buprenorphine for a long period of time can lead to physical dependence, with withdrawal symptoms when it is stopped suddenly. It can also cause significant respiratory depression and even death if taken in large doses or when combined with other substances like benzodiazepines or alcohol. Buprenorphine can cause constipation, decreased sex drive
How Zubsolv works in the bodyBuprenorphine is a drug that binds to the same nerve receptors as other opioids, like heroin, oxycodone and methadone. However, it doesn't activate these receptors as much as these other opioids, which means it has a slower onset and a "ceiling effect" - a point at which the effects of the drug stop increasing. This makes it less likely to cause overdose, and the lower activation of the receptors means it doesn't cause as much sedation or euphoria. Buprenorphine can cause a rapid withdrawal if taken by someone who's already dependent on opioids, so it's important that they

When to interrupt dosage

The measure of Zubsolv depends on the diagnosed affliction, including Pain, Pain and Opioid Dependence. The quantity of dosage likewise varies as indicated by the method of delivery (e.g. Tablet - Oral or Sublingual) specified in the table beneath.
Condition
Dosage
Administration
Itching
, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL
, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Solution, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Buccal, Film, Film - Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Parenteral; Topical, Inhalant, Inhalant - Nasal
Pain
, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL
, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Solution, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Buccal, Film, Film - Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Parenteral; Topical, Inhalant, Inhalant - Nasal
Pain
, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL
, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Solution, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Buccal, Film, Film - Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Parenteral; Topical, Inhalant, Inhalant - Nasal
Septic Shock
, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL
, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Solution, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Buccal, Film, Film - Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Parenteral; Topical, Inhalant, Inhalant - Nasal
Respiratory Insufficiency
, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL
, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Solution, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Buccal, Film, Film - Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Parenteral; Topical, Inhalant, Inhalant - Nasal
Opioid-Related Disorders
, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL
, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Solution, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Buccal, Film, Film - Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Parenteral; Topical, Inhalant, Inhalant - Nasal
Opioids
, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL
, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Solution, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Buccal, Film, Film - Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Parenteral; Topical, Inhalant, Inhalant - Nasal
Opioids
, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL
, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Solution, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Buccal, Film, Film - Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Parenteral; Topical, Inhalant, Inhalant - Nasal
Emergency Care
, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL
, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Solution, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Buccal, Film, Film - Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Parenteral; Topical, Inhalant, Inhalant - Nasal
Opioids
, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL
, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Solution, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Buccal, Film, Film - Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Parenteral; Topical, Inhalant, Inhalant - Nasal

Warnings

Zubsolv has twenty-two contraindications and should not be ingested when enduring any of the ailments outlined in the subsequent table.Zubsolv Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Naloxone may interact with Pulse Frequency
There are 20 known major drug interactions with Zubsolv.
Common Zubsolv Drug Interactions
Drug Name
Risk Level
Description
(R)-warfarin
Major
The metabolism of (R)-warfarin can be decreased when combined with Naloxone.
(S)-Warfarin
Major
The metabolism of (S)-Warfarin can be decreased when combined with Naloxone.
1,2-Benzodiazepine
Major
The metabolism of 1,2-Benzodiazepine can be decreased when combined with Naloxone.
3,5-diiodothyropropionic acid
Major
The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Naloxone.
5-androstenedione
Major
The metabolism of 5-androstenedione can be decreased when combined with Naloxone.
Zubsolv Toxicity & Overdose RiskSigns of an acute overdose of morphine include small pupils, drowsiness, low blood pressure, and difficulty breathing. If left untreated, it can lead to death.
image of a doctor in a lab doing drug, clinical research

Zubsolv Novel Uses: Which Conditions Have a Clinical Trial Featuring Zubsolv?

Currently, 21 active studies are assessing the potential of Zubsolv for treating Opioid Dependence, Pain and Palliative Care.
Condition
Clinical Trials
Trial Phases
Emergency Care
0 Actively Recruiting
Opioids
0 Actively Recruiting
Opioid-Related Disorders
0 Actively Recruiting
Septic Shock
0 Actively Recruiting
Respiratory Insufficiency
0 Actively Recruiting
Itching
2 Actively Recruiting
Phase 3, Not Applicable
Pain
0 Actively Recruiting
Opioids
7 Actively Recruiting
Phase 4, Not Applicable, Phase 2, Phase 1
Opioids
5 Actively Recruiting
Phase 2, Not Applicable, Early Phase 1
Pain
0 Actively Recruiting

Zubsolv Reviews: What are patients saying about Zubsolv?

5Patient Review
4/6/2017
Zubsolv for Narcotic Addiction
Zubsolv has been a game-changer for me. I was on suboxone twice before and relapsed both times, but this third time feels different. Zubsolv doesn't make me feel as terrible as suboxone did, and I'm finally starting to see progress in my recovery.
5Patient Review
4/7/2017
Zubsolv for Prevention of Opiate Drug Abuse
I feel like this drug has helped me more than any other I've tried. Zubsolv is definitely the way to go if you're looking to get off drugs.
5Patient Review
7/30/2014
Zubsolv for Narcotic Addiction
I switched from Sub to Zub on 7/1/14 when my insurance stopped covering the former. I find Zub WAY more effective: it tastes better, dissolves faster, and gets into my bloodstream quickly. I was on 16mg Sub and now 10mg of Zub and can tell NO difference. The only downside is that it's hard to open the package.
5Patient Review
5/1/2019
Zubsolv for Prevention of Opiate Drug Abuse
This medication has been integral in my sobriety. It curbs cravings and helps me feel more confident about my ability to stay clean. I highly recommend it to anyone who is addicted or trying to stay sober.
5Patient Review
12/11/2019
Zubsolv for Narcotic Addiction
These pills have completely changed my life for the better. I highly recommend them to anyone struggling with addiction.
4.7Patient Review
7/31/2015
Zubsolv for Narcotic Addiction
I've been on zubsolv for almost a year now and I much prefer it to sub. To me, it lasts longer and tastes better. Additionally, I get a bit of a rush from it unlike sub which made me incredibly tired. The only problem with zub is that my pharmacy isn't always well-stocked with it.
4Patient Review
7/31/2017
Zubsolv for Narcotic Addiction
Suboxone is my preferred treatment, but Zubsolv works just as well. The only downside is that the tablets are not as easy to use as the strips.
1.7Patient Review
11/11/2022
Zubsolv for Chronic Pain
Subutol was a terrible experience for me. It made my headaches and muscle pain in my legs worse, sapped all my energy, and made it hard to get out of bed or focus on anything. I got back on Suboxone and within two days felt one hundred percent better.
1.3Patient Review
8/3/2015
Zubsolv for Chronic Pain
Suboxone was a huge disappointment. I experienced intense water retention, raw tongue and swelling, lethargy, lack of energy, withdrawal symptoms, no pain relief, vision problems, constipation, irritability, and difficulty opening the packaging.
1Patient Review
1/18/2015
Zubsolv for Prevention of Opiate Drug Abuse
I was recently switched to Zubsolv because my insurance stopped covering name brand Suboxone films and then the generic Suboxone tablets. I hate the minty taste and i've been depressed since switching last week. I have been having trouble sleeping and for the first time in years i'm experiencing withdrawls again.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zubsolv

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Zubsolv?

"You may experience the following symptoms: dizziness, drowsiness, blurred vision, feeling drunk, trouble concentrating, withdrawal symptoms, tongue pain, redness or numbness inside your mouth, nausea, vomiting, constipation, headache, back pain, fast or pounding heartbeats, increased sweating, or sleep problems (insomnia)."

Answered by AI

How does Zubsolv make you feel?

"However, people taking buprenorphine in studies have reported some emotional side effects, such as anxiety, depression, and nervousness. Additionally, people going through withdrawal may also experience these emotions. withdrawal from buprenorphine can cause anxiety."

Answered by AI

What is Zubsolv used for?

"Naloxone reverses the effects of opioids and can cause withdrawal symptoms in people who take opioids.

This drug is a combination of two medicines, buprenorphine and naloxone, and is used to treat dependence or addiction to opioids. Buprenorphine is a drug that belongs to a class of mixed opioid agonist-antagonists, meaning that it helps to prevent withdrawal symptoms caused by quitting other opioids. Naloxone, on the other hand, reverses the effects of opioids and can actually cause withdrawal symptoms in people who take opioids regularly."

Answered by AI

Does Zubsolv have Narcan in it?

"Zubsolv contains two active drugs: buprenorphine and naloxone. Zubsolv comes in six strengths, which contain different amounts (in milligrams) of the drugs. The lowest strength contains 0.7 mg of buprenorphine and 0.18 mg of naloxone."

Answered by AI

Clinical Trials for Zubsolv

Image of Swedish American Hospital in Rockford, United States.

MedSMAâ„žT Mobile for Opioid Addiction

Any Age
All Sexes
Rockford, IL
The goal of this clinical trial is to learn if a new smartphone-based intervention can help with factors related to opioid misuse in parents and adolescent/early adult children. The main question it aims to answer is: • Can this intervention improve knowledge of, and attitudes towards, opioid misuse over traditional opioid-related counseling alone? Participants will, in addition to receiving opioid counseling: * Join an online meeting with research staff to test the smartphone-based intervention * Report demographic information * Complete surveys about opioids * Complete a family medication safety plan * Complete surveys after 3, 6, and 9 months
Waitlist Available
Has No Placebo
Swedish American Hospital (+2 Sites)Olufunmilola Abraham, PhD
Image of Toronto General Hospital in Toronto, Canada.

Transcutaneous Electrical Stimulation for Slow Breathing

18+
All Sexes
Toronto, Canada
After surgery, patients often recover in a special area called the Post Anesthesia Care Unit (PACU). Patients may receive pain medications either during the surgery or afterward in the PACU. While these medications are important for controlling pain, some of them can slow down breathing. To ensure patients' breathing remains safe, the nurses in the PACU monitor respiratory rate (how many breaths a patient takes per minute) and oxygen levels using standard monitoring equipment. This is the usual way they check for breathing concerns. If these monitors show that a patient's breathing has slowed down too much, nurses may wake the patient up or stimulate them using their voice or gentle physical touch to encourage deeper breaths. What is this study about? This research is testing a new approach that uses an additional monitor called capnography. Capnography helps detect slowing or stopping of breathing by measuring the carbon dioxide (CO2) exhaled by patients. If the monitor shows slowed or stopped breathing (called apnea, lasting at least 10 seconds), this study will test using a technology called transcutaneous electrical stimulation (TES) to encourage normal breathing. How does TES work? TES provides a slight, annoying sensation on the patient's skin-enough to wake them up without causing pain. This has been used in other studies to safely restore breathing after surgery. In this study, the researchers are testing whether a new automated device can deliver TES when the capnography monitor detects breathing issues. The goal is to test the feasibility (can this system work in the PACU?) and acceptability (how do patients feel about this approach?) of this technology. Who can join this study? Adults aged 18 or older who received general anesthesia and medications (opioids) for pain control during or after surgery are eligible. Patients recovering from surgery in the PACU at Toronto General Hospital may be invited to participate. Why is this study important? The study aims to reduce the risk of opioid-related breathing problems after surgery, making recovery safer and more comfortable for patients.
Recruiting
Has No Placebo
Toronto General Hospital
Have you considered Zubsolv clinical trials? We made a collection of clinical trials featuring Zubsolv, we think they might fit your search criteria.Go to Trials
Image of Pennsylvania Psychiatric Institute in Harrisburg, United States.

Semaglutide for Opioid Addiction

18 - 75
All Sexes
Harrisburg, PA
The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids? The investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semaglutide works to reduce use of illicit and nonprescribed opioids. The participants will: * Take semaglutide or a placebo every week for 12 weeks * Visit the clinic every week for urine drug screening and pregnancy testing, vital signs, and to complete mental health and drug use questionnaires * Complete smartphone surveys sent at set times during the study
Phase 2
Recruiting
Pennsylvania Psychiatric Institute (+2 Sites)Jennifer Nyland, PhD
Have you considered Zubsolv clinical trials? We made a collection of clinical trials featuring Zubsolv, we think they might fit your search criteria.Go to Trials
Image of Ewald & Wasserman Research Consultants, LLC in San Francisco, United States.

Naloxone Training for Opioid Overdose

18 - 100
All Sexes
San Francisco, CA
The pervasive impact of the opioid epidemic has touched all layers of society for the past two decades, resulting in over 115 deaths daily and imposing annual costs of $78.5 billion. Responding swiftly to overdoses, akin to various medical emergencies, poses a significant challenge, particularly in geographically dispersed rural areas and densely populated urban settings. Effectively delivering the life-saving drug naloxone, which counteracts the effects of overdoses, necessitates a well-coordinated and cost-efficient response system. Simply opting for widespread distribution of naloxone, even with citizen involvement, proves to be a financially burdensome approach when compared to more targeted strategies. Moreover, obstacles such as limited access, inadequate or unavailable naloxone training, and delayed response times from emergency responders compound the problem. Addressing these issues, the proposed Opioid Rapid Response System (ORRS) project seeks to advance prevention science by adopting an innovative approach that incorporates technology and contemporary communication theory. The primary objective of the ORRS project is to mitigate opioid overdose deaths by enlisting and training citizens to administer naloxone in response to such events. Leveraging the PulsePoint health app, which connects citizens to cardiac events, the ORRS project will extend its capabilities to respond to overdose incidents. This initiative involves comprehensive development of ORRS, followed by a randomized clinical trial on a national scale to assess its effectiveness. The study aims to contribute to both prevention and implementation science by identifying optimal recruitment strategies and testing a model of online training. In pursuit of these objectives, the study is guided by the following Specific Aims: SA 1: Refine and complete the development of ORRS. SA 2: Conduct a randomized clinical trial to evaluate the effectiveness of the intervention. SA 3: Prepare ORRS for dissemination.
Waitlist Available
Paid Trial
Ewald & Wasserman Research Consultants, LLCHye Jeong Choi
Image of Hartford Hospital Emergency Department in Hartford, United States.

Overdose Education for Opioid Overdose

21 - 65
All Sexes
Hartford, CT
While there is a lifesaving medication called naloxone that can reverse the deadly effects of opioid overdose, patients often fail to fill the prescription at the pharmacy when it is prescribed. This is particularly concerning and true in those at the highest risk of death-those who end up in the emergency department for opioid overdose. The goal of this study is to compare the impact of different overdose education on naloxone prescription fill rates in opioid users being discharged from our hospital emergency department. You will receive either (a) written education about naloxone through their MyChart account, or (b) a concise one-page handout and 4-minute video clip reviewed with the participant and a support individual (family/friend) prior to discharge.
Recruiting
Has No Placebo
Hartford Hospital Emergency Department (+1 Sites)Jonathan C Allen, MD
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security